Enables phosphoprotein phosphatase activity; protein phosphatase 1 binding activity; and ribonucleoprotein complex binding activity. Involved in protein dephosphorylation; regulation of glycogen metabolic process; and response to lead ion. Located in dendritic spine; glycogen granule; and perikaryon. Part of protein phosphatase type 1 complex. Is active in glutamatergic synapse; postsynapse; and presynapse. Orthologous to human PPP1CA (protein phosphatase 1 catalytic subunit alpha); PARTICIPATES IN glycogen biosynthetic pathway; glycogen degradation pathway; adenosine monophosphate-activated protein kinase (AMPK) signaling pathway; INTERACTS WITH 1,3-dinitrobenzene; 2,3,7,8-tetrachlorodibenzodioxine; ammonium chloride.
2-bromopalmitate inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased palmitoylation of PPP1CA protein]
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of PPP1CA mRNA
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of PPP1CA protein
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of PPP1CA mRNA
2-bromopalmitate inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased palmitoylation of PPP1CA protein] and [Cadmium Chloride results in increased abundance of Cadmium] which results in increased palmitoylation of PPP1CA protein
2-bromopalmitate inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased palmitoylation of PPP1CA protein] and [Cadmium Chloride results in increased abundance of Cadmium] which results in increased palmitoylation of PPP1CA protein
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of PPP1CA mRNA
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of PPP1CA protein
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of PPP1CA mRNA
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of PPP1CA protein
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of PPP1CA protein
titanium dioxide results in decreased methylation of PPP1CA gene and titanium dioxide results in decreased methylation of PPP1CA promoter alternative form
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of PPP1CA protein
Molecular cloning and sequence analysis of cDNA for the catalytic subunit 1 alpha of rat kidney type 1 protein phosphatase, and detection of the gene expression at high levels in hepatoma cells and regenerating livers as compared to rat livers.
Over activation of hippocampal serine/threonine protein phosphatases PP1 and PP2A is involved in lead-induced deficits in learning and memory in young rats.
Identification of members of the protein phosphatase 1 gene family in the rat and enhanced expression of protein phosphatase 1 alpha gene in rat hepatocellular carcinomas.
